Latest News & Features
Biotechnology
Birmingham—Britain’s second city—with a leading university for research and development, allows biotech companies to enjoy the benefits of a cluster, as James Wilkie, CEO of Alta Innovations, the commercial spinout of the University of Birmingham, told LSIPR. 5 June 2016
Americas
Mexico and other signatories to the TPP face a number of challenges on the IP front in implementing its reforms, as Iliana Ramirez Villaseñor of Leyva, Montenegro, Trigueros Abogados reports. 3 June 2016
Europe
In Russia, more attention is being paid towards the correlation between IP rights and competition restrictions, and pharma companies should keep abreast of developments, says Ilya Goryachev of Gorodissky & Partners. 3 June 2016
Americas
President Barack Obama has praised scientists and the technology industry at the honorary ceremony for scientists at the White House. 2 June 2016
Big Pharma
National Health Service England has been criticised after announcing its decision that it will not be providing the HIV treatment Truvada, which enables pre-exposure prophylaxis. 2 June 2016
Americas
Law firm Fox Rothschild has hired Patrick Birde, Deborah Somerville and Christopher Glynn as partners in the firm’s intellectual property practice. 2 June 2016
Americas
A pending case at the US Court of Appeals for the Federal Circuit may give the pharmaceutical and biotechnology industry important guidance on issues surrounding third-party contract manufacturing and the on-sale bar to patentability, as Porter Fleming and Jason Kanter of Frommer Lawrence & Haug report. 2 June 2016
Big Pharma
With the UK set to decide on whether it wants to be in or out of Europe, Jane Wainwright and Tom Harding of Potter Clarkson examine how politics is shaping IP in Europe. 2 June 2016
article
Minesoft’s Chemical Explorer helps users to find chemical information in patents issued by multiple authorities. Robert Poolman explains how it works. 2 June 2016
Americas
Jazz Pharmaceuticals, based in Ireland, will buy US company Celator Pharmaceuticals for $1.5 billion in cash. 1 June 2016